Supplementary Table 1. Population characteristics according to hospitalization status.

	Total Cohort (n: 2,782)	No Hospitalization (n: 1,577)	All-cause Hospitalization (n: 1,205)	p-value
Female sex (%)	43.5	43.9	43.1	0.671
Age (mean)	74.6±9.1	74.7±9.4	74.5±8.6	0.565
Permanent/persistent AF (%)	62.8	62.8	62.7	1.000
Arterial hypertension (%)	86.7	85.5	88.4	0.024
Diabetes (%)	21.3	19.6	23.6	0.012
Previous stroke/TIA (%)	15.1	14.7	15.7	0.455
Previous myocardial infarction (%)	17.1	15.5	19.1	0.013
COPD (%)	15.1	12.5	18.3	<0.001
Cancer (%)	16.4	12.8	21.0	<0.001
Heart failure (%)	14.1	12.6	16.0	0.011
CKD (%)	32.9	31.5	34.5	0.142
CHA$_2$DS$_2$-VASc (mean)	3.6±1.5	3.5±1.5	3.7±1.5	0.001
HAS-BLED (mean)	2.3±0.9	2.2±0.8	2.4±0.9	<0.001
Therapy				
DOAC (%)	33.1	39.1	25.1	<0.001
Lipid lowering therapy (%)	39.3	38.2	40.7	0.183
ACE-I/ARBs (%)	62.7	59.8	66.4	<0.001
Beta-blockers (%)	44.8	45.3	44.2	0.590
Calcium channel blockers (%)	27.7	26.1	30.0	0.024
Verapamil/diltiazem (%)	9.8	9.5	10.3	0.468
Nitrates (%)	9.8	7.9	12.2	<0.001
Antiarrhythmics (%)	27.6	25.8	29.7	0.027
Ic Class	13.4	13.1	13.9	0.501
Amiodarone	14.4	13.4	15.i8	0.076
Digoxin (%)	13.6	12.5	15.1	0.047
Hypoglycemic drugs (%)	16.6	15.2	18.3	0.050
Diuretics (%)	43.6	42.7	44.6	0.316
Proton pump inhibitor (%)	44.8	45.8	43.5	0.233

ACE-I/ARBs: angiotensin converting enzyme inhibitors/Angiotensin receptor blockers, COPD: chronic obstructive pulmonary disease, DOAC: direct oral anticoagulant.

Supplementary Table 2. Multivariable Cox proportional hazards regression analysis of cardiac hospitalization.

	Hazard Ratio	95% Confidence interval		p-value
		Low	High	
Age	1.006	0.996	1.017	0.255
Female sex	0.936	0.781	1.123	0.478
Arterial hypertension	1.206	0.875	1.661	0.253
Diabetes	1.036	0.837	1.281	0.746
Previous myocardial infarction	1.189	0.926	1.527	0.174
COPD	1.396	1.110	1.757	0.004
Cancer	1.194	0.953	1.497	0.124
Heart failure	1.364	1.076	1.729	0.010
ACE-I/ARB	1.002	0.817	1.229	0.984
Nitrates	0.997	0.757	1.314	0.983
Ic Class antiarrhythmics	1.386	1.074	1.789	0.012
Amiodarone	1.495	1.197	1.868	<0.001
Beta-blockers	1.033	0.853	1.250	0.742
Verapamil/diltiazem	0.990	0.724	1.353	0.949
Digoxin	1,243	0.977	1.581	0.076
DOAC vs VKA	0.586	0.468	0.733	<0.001
Lipid lowering therapy	1.087	0.897	1.317	0.396

ACE-I/ARBs: angiotensin converting enzyme inhibitors/Angiotensin receptor blockers, COPD: chronic obstructive pulmonary disease, DOAC: direct oral anticoagulant, VKA: vitamin K antagonist.